Vivoryon Therapeutics N.V. (0R3M.L)

EUR 1.77

(-0.56%)

Operating Expenses Summary of Vivoryon Therapeutics N.V.

Vivoryon Therapeutics N.V.'s latest annual operating expenses in 2023 was 24.69 Million EUR , down -9.85% from previous year.
Vivoryon Therapeutics N.V.'s latest quarterly operating expenses in 2024 Q2 was 13.8 Million EUR , down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported a annual operating expenses of 28.97 Million EUR in annual operating expenses 2022, up 32.68% from previous year.
Vivoryon Therapeutics N.V. reported a annual operating expenses of 21.83 Million EUR in annual operating expenses 2021, up 37.58% from previous year.
Vivoryon Therapeutics N.V. reported a quarterly operating expenses of 10.61 Million EUR for 2023 Q2, down 0.0% from previous quarter.
Vivoryon Therapeutics N.V. reported a quarterly operating expenses of 26.11 Million EUR for 2023 FY, down -9.85% from previous quarter.

Annual Operating Expenses Chart of Vivoryon Therapeutics N.V. (2023 - 2011)

Historical Annual Operating Expenses of Vivoryon Therapeutics N.V. (2023 - 2011)

Year	Operating Expenses	Operating Expenses Growth
2023	24.69 Million EUR	-9.85%
2022	28.97 Million EUR	32.68%
2021	21.83 Million EUR	37.58%
2020	15.87 Million EUR	106.49%
2019	7.68 Million EUR	-0.23%
2018	7.7 Million EUR	-21.86%
2017	9.85 Million EUR	-28.37%
2016	13.76 Million EUR	2.85%
2015	13.38 Million EUR	18.76%
2014	11.26 Million EUR	16.74%
2013	9.65 Million EUR	-8.64%
2012	10.56 Million EUR	-26.07%
2011	14.29 Million EUR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	13.8 Million EUR	0.0%
2023 Q2	10.61 Million EUR	0.0%
2023 FY	26.11 Million EUR	-9.85%
2023 Q4	15.07 Million EUR	0.0%
2022 FY	28.97 Million EUR	32.68%
2022 Q2	13.29 Million EUR	0.0%
2022 Q4	15.67 Million EUR	0.0%
2021 Q4	10.12 Million EUR	0.0%
2021 Q2	11.71 Million EUR	0.0%
2021 FY	21.83 Million EUR	37.58%
2020 FY	15.87 Million EUR	106.49%
2020 Q4	8.41 Million EUR	0.0%
2020 Q2	7.45 Million EUR	0.0%
2019 Q4	4.62 Million EUR	0.0%
2019 FY	7.68 Million EUR	-0.23%
2019 Q2	3.06 Million EUR	0.0%
2018 Q2	4.13 Million EUR	0.0%
2018 Q4	3.56 Million EUR	0.0%
2018 FY	7.7 Million EUR	-21.86%
2017 Q2	6.26 Million EUR	0.0%
2017 FY	9.85 Million EUR	-28.37%
2017 Q4	3.69 Million EUR	0.0%
2016 FY	13.76 Million EUR	2.85%
2016 Q4	7.79 Million EUR	0.0%
2016 Q2	5.98 Million EUR	0.0%
2015 FY	13.38 Million EUR	18.76%
2015 Q2	6.17 Million EUR	0.0%
2015 Q4	7.21 Million EUR	0.0%
2014 Q2	3.73 Million EUR	0.0%
2014 FY	11.26 Million EUR	16.74%
2014 Q4	7.52 Million EUR	0.0%
2013 Q4	4.88 Million EUR	21824.44%
2013 FY	9.65 Million EUR	-8.64%
2013 Q3	-22.5 Thousand EUR	-100.47%
2013 Q2	4.76 Million EUR	21268.89%
2013 Q1	-22.5 Thousand EUR	0.0%
2012 Q1	-49.75 Thousand EUR	0.0%
2012 Q3	-49.75 Thousand EUR	0.0%
2012 Q4	-22.5 Thousand EUR	54.77%
2012 FY	10.56 Million EUR	-26.07%
2012 Q2	-49.75 Thousand EUR	0.0%
2011 Q4	-49.75 Thousand EUR	-101.39%
2011 Q1	3.57 Million EUR	0.0%
2011 Q3	3.57 Million EUR	0.0%
2011 Q2	3.57 Million EUR	0.0%
2011 FY	14.29 Million EUR	0.0%
2010 Q4	3.57 Million EUR	0.0%

Peer Operating Expenses Comparison of Vivoryon Therapeutics N.V.

Name	Operating Expenses	Operating Expenses Difference
Boiron SA	317.27 Million EUR	92.217%
Laboratorios Farmaceuticos Rovi, S.A.	263.09 Million EUR	90.615%
Vetoquinol SA	217.11 Million EUR	88.627%
Valneva SE	134.92 Million EUR	81.699%
AB Science S.A.	14.01 Million EUR	-76.17%
Nanobiotix S.A.	62.98 Million EUR	60.798%
PHAXIAM Therapeutics S.A.	24.98 Million EUR	1.177%
BioSenic S.A.	7.58 Million EUR	-225.623%
ABIVAX Société Anonyme	127.37 Million EUR	80.615%
Formycon AG	23.73 Million EUR	-4.041%